Revenue of $699 million; 2% reported growth; 1% organic growth
GAAP EPS of $0.40; Adjusted EPS from continuing operations of $1.18
Reaffirms full year 2025 organic growth and raises adjusted EPS guidance
Authorizes new $1 billion share repurchase program

Revvity, Inc. (NYSE:RVTY), today reported financial results for the third quarter ended September 28, 2025.

The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP operating profit margin from continuing operations was 11.7% as a percentage of revenue, as compared to 14.3% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.18, as compared to $1.28 in the same period a year ago. Adjusted operating income was $182 million, as compared to $193 million for the same period a year ago. Adjusted operating profit margin was 26.1% as a percentage of revenue, as compared to 28.3% in the same period a year ago.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

"We performed well during the third quarter as a number of key innovations and strategic partnerships have begun to come to fruition," said Prahlad Singh, president and chief executive officer of Revvity. "Our strong level of execution is positioning the Company for even greater success in 2026 and beyond."

Share Repurchase Authorization

The Company's Board of Directors has authorized a new two-year $1 billion share repurchase program which replaces the remainder of the prior repurchase program which was announced in October 2024.

Financial Overview by Reporting Segment

Life Sciences

Third quarter 2025 revenue was $343 million, as compared to $339 million in the same period a year ago. Revenue increased 1% and organic revenue was flat as compared to the same period a year ago.

Third quarter 2025 adjusted operating income was $101 million, as compared to $111 million in the same period a year ago. Adjusted operating profit margin was 29.5% as a percentage of revenue, as compared to 32.6% in the same period a year ago.

Diagnostics

Third quarter 2025 revenue was $356 million, as compared to $345 million in the same period a year ago. Revenue increased 3% and organic revenue increased 2% as compared to the same period a year ago.

Third quarter 2025 adjusted operating income was $89 million, as compared to $94 million in the same period a year ago. Adjusted operating profit margin was 25.1% as a percentage of revenue, as compared to 27.2% in the same period a year ago.

Full Year 2025 Guidance

For the full year 2025, the Company is updating its full year revenue guidance to $2.83-$2.88 billion to reflect recent changes in foreign currency exchange rates and is reaffirming its organic growth guidance of 2% to 4%. The Company is also raising its adjusted EPS guidance to a range of $4.90 to $5.00.

Guidance for the full year 2025 for adjusted EPS and organic growth is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its third quarter 2025 results and its outlook for business trends during a webcast on October 27, 2025, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes", "intends", "anticipates", "plans", "expects", "estimates", "projects", "forecasts", "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments, including as the result of recently implemented and recently threatened tariff increases; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED INCOME STATEMENTS

	Three Months Ended						Nine Months Ended
(In thousands, except per share data)	September 28, 2025			September 29, 2024			September 28, 2025			September 29, 2024

Revenue	$	698,949		$	684,049		$	2,083,995		$	2,025,654

Cost of revenue		324,345			299,233			941,289			900,285
Selling, general and administrative expenses		241,911			237,521			740,156			749,742
Research and development expenses		50,797			49,144			157,664			147,636

Operating income from continuing operations		81,896			98,151			244,886			227,991

Interest income		(6,925	)		(22,764	)		(25,351	)		(63,362	)
Interest expense		22,771			24,383			68,672			73,497
Change in fair value of investments		4,602			(7,004	)		3,484			(13,975	)
Other expense, net		5,763			3,179			21,364			10,263

Income from continuing operations, before income taxes		55,685			100,357			176,717			221,568

Provision for income taxes		8,464			6,971			32,605			26,880

Income from continuing operations		47,221			93,386			144,112			194,688

(Loss) income from discontinued operations		(569	)		981			(1,275	)		(18,948	)

Net income	$	46,652		$	94,367		$	142,837		$	175,740

*Diluted earnings per share:*

Income from continuing operations	$	0.41		$	0.76		$	1.22		$	1.58

(Loss) income from discontinued operations		(0.01	)		0.01			(0.01	)		(0.15	)

Net income	$	0.40		$	0.77		$	1.21		$	1.42

Weighted average diluted shares of common stock outstanding		115,463			123,026			117,735			123,336


ABOVE PREPARED IN ACCORDANCE WITH GAAP


Additional supplemental information⁽¹⁾:
(per share, continuing operations)

GAAP EPS from continuing operations	$	0.41		$	0.76		$	1.22		$	1.58
Amortization of intangible assets		0.73			0.73			2.14			2.20
Purchase accounting adjustments		—			—			0.02			0.06
Acquisition and divestiture-related costs		—			0.02			0.02			0.13
Transformation costs		0.04			—			0.05			—
Change in fair value of investments		0.04			(0.06	)		0.03			(0.11	)
Significant litigation matters and settlements		0.01			0.01			0.11			0.06
Significant environmental matters		—			—			(0.01	)		—
Mark to market on postretirement benefits		—			—			0.04			—
Restructuring and other, net		0.09			—			0.21			0.18
Tax on above items		(0.17	)		(0.18	)		(0.49	)		(0.62	)
Significant tax items		0.03			—			0.03			—
Adjusted EPS from continuing operations	$	1.18		$	1.28		$	3.37		$	3.47

(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries REVENUE AND OPERATING INCOME (LOSS)

	Three Months Ended						Nine Months Ended
(In thousands, except percentages)	September 28, 2025			September 29, 2024			September 28, 2025			September 29, 2024

Revenue and adjusted operating income

Revenue	$	698,949		$	684,049		$	2,083,995		$	2,025,654

Reported operating income from continuing operations	$	81,896		$	98,151		$	244,886		$	227,991
OP%		11.7	%		14.3	%		11.8	%		11.3	%
Amortization of intangible assets		84,074			89,642			252,063			271,500
Purchase accounting adjustments		348			103			2,349			7,348
Acquisition and divestiture-related costs		284			4,874			2,950			22,115
Transformation costs		5,103			—			6,226			—
Significant litigation matters and settlements		785			810			12,495			7,086
Significant environmental matters		—			—			(1,208	)		—
Restructuring and other, net		9,926			(82	)		24,368			22,119
Adjusted operating income	$	182,416		$	193,498		$	544,129		$	558,159
OP%		26.1	%		28.3	%		26.1	%		27.6	%

Segment revenue and segment operating income

Life Sciences	$	342,822		$	338,800		$	1,049,115		$	1,023,839
Diagnostics		356,127			345,249			1,034,880			1,001,815
Segment revenue		698,949			684,049			2,083,995			2,025,654

Life Sciences	$	101,048		$	110,565		$	322,228		$	329,083
		29.5	%		32.6	%		30.7	%		32.1	%
Diagnostics		89,376			93,848			252,813			262,801
		25.1	%		27.2	%		24.4	%		26.2	%
Segment operating income		190,424			204,413			575,041			591,884

Corporate		(8,008	)		(10,915	)		(30,912	)		(33,725	)
Adjusted operating income		182,416			193,498			544,129			558,159

Amortization of intangible assets		(84,074	)		(89,642	)		(252,063	)		(271,500	)
Purchase accounting adjustments		(348	)		(103	)		(2,349	)		(7,348	)
Acquisition and divestiture-related costs		(284	)		(4,874	)		(2,950	)		(22,115	)
Transformation costs		(5,103	)		—			(6,226	)		—
Significant litigation matters and settlements		(785	)		(810	)		(12,495	)		(7,086	)
Significant environmental matters		—			—			1,208			—
Restructuring and other, net		(9,926	)		82			(24,368	)		(22,119	)
Reported operating income from continuing operations	$	81,896		$	98,151		$	244,886		$	227,991


REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)	September 28, 2025		December 29, 2024

Current assets:
Cash and cash equivalents	$	931,386	$	1,163,396
Accounts receivable, net		680,259		632,400
Inventories, net		379,917		367,587
Other current assets		152,226		186,225
Total current assets		2,143,788		2,349,608

Property, plant and equipment, net		497,088		482,217
Operating lease right-of-use assets, net		171,078		167,716
Intangible assets, net		2,425,926		2,640,921
Goodwill		6,600,631		6,463,619
Other assets, net		300,441		288,397
Total assets	$	12,138,952	$	12,392,478

Current liabilities:
Current portion of long-term debt	$	583,844	$	242
Accounts payable		175,800		167,463
Accrued expenses and other current liabilities		463,099		485,395
Total current liabilities		1,222,743		653,100

Long-term debt		2,630,693		3,150,476
Long-term liabilities		755,155		770,523
Operating lease liabilities		154,465		151,505
Total liabilities		4,763,056		4,725,604

Total stockholders' equity		7,375,896		7,666,874
Total liabilities and stockholders' equity	$	12,138,952	$	12,392,478


PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three Months Ended						Nine Months Ended
(In thousands)	September 28, 2025			September 29, 2024			September 28, 2025			September 29, 2024

Operating activities:
Net income	$	46,652		$	94,367		$	142,837		$	175,740
Loss (income) from discontinued operations, net of income taxes		569			(981	)		1,275			18,948
Income from continuing operations		47,221			93,386			144,112			194,688
Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:
Stock-based compensation		9,054			10,538			26,918			32,756
Restructuring and other, net		9,926			(82	)		24,368			22,119
Depreciation and amortization		102,061			107,670			302,261			322,816
Change in fair value of contingent consideration		107			(343	)		(59	)		6,006
Amortization of deferred debt financing costs and accretion of discounts		1,240			1,542			3,560			5,051
Change in fair value of investments		4,602			(7,004	)		3,484			(13,975	)
Unrealized foreign exchange loss (gain)		82			(206	)		222			(1,063	)
Changes in assets and liabilities which provided (used) cash:
Accounts receivable, net		(19,742	)		5,097			(41,643	)		33,291
Inventories, net		6,851			9,566			12,493			26,817
Accounts payable		(3,008	)		(1,808	)		270			(24,782	)
Accrued expenses and other		(19,813	)		(61,342	)		(68,990	)		(114,236	)
Net cash provided by operating activities of continuing operations		138,581			157,014			406,996			489,488
Net cash used in operating activities of discontinued operations		(81	)		(9,129	)		(6,023	)		(35,419	)
Net cash provided by operating activities		138,500			147,885			400,973			454,069

Investing activities:
Capital expenditures		(18,501	)		(22,319	)		(53,351	)		(62,194	)
Purchases of investments and notes receivables		(29	)		—			(29	)		(4,337	)
Proceeds from investments and notes receivables		—			2,500			—			2,500
Proceeds from U.S. Treasury Securities		—			710,000			—			710,000
Proceeds from disposition of businesses and assets		—			—			229			—
Net cash (used in) provided by investing activities of continuing operations		(18,530	)		690,181			(53,151	)		645,969
Net cash provided by investing activities of discontinued operations		37,500			—			56,250			147,522
Net cash provided by investing activities		18,970			690,181			3,099			793,491

Financing Activities:
Payments of debt financing costs		—			—			(2,474	)		—
Payments of senior unsecured notes		—			(711,479	)		—			(711,479	)
Payments on other credit facilities		(55	)		429			(158	)		(10,771	)
Payments for acquisition-related contingent consideration		(1,860	)		(83	)		(3,838	)		(8,832	)
Proceeds from issuance of common stock under stock plans		—			141			2,632			6,173
Purchases of common stock		(205,029	)		(154,112	)		(652,530	)		(184,421	)
Dividends paid		(8,130	)		(8,633	)		(24,845	)		(25,915	)
Net cash used in financing activities of continuing operations		(215,074	)		(873,737	)		(681,213	)		(935,245	)

Effect of exchange rate changes on cash, cash equivalents, and restricted cash		(2,811	)		17,051			45,264			4,120

Net (decrease) increase in cash, cash equivalents, and restricted cash		(60,415	)		(18,620	)		(231,877	)		316,435
Cash, cash equivalents, and restricted cash at beginning of period		992,990			1,249,428			1,164,452			914,373
Cash, cash equivalents, and restricted cash at end of period	$	932,575		$	1,230,808		$	932,575		$	1,230,808


Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the condensed balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents	$	931,386		$	1,229,778		$	931,386		$	1,229,778
Restricted cash included in other current assets		1,189			1,030			1,189			1,030
Total cash, cash equivalents and restricted cash	$	932,575		$	1,230,808		$	932,575		$	1,230,808


PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

			Continuing Operations
			Three Months Ended
			September 28, 2025
Organic revenue growth:
Revenue growth from continuing operations			2%
Less: effect of foreign exchange rates			1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			1%


			Life Sciences
			Three Months Ended
			September 28, 2025
Organic revenue growth:
Revenue growth from continuing operations			1%
Less: effect of foreign exchange rates			1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			0%


			Diagnostics
			Three Months Ended
			September 28, 2025
Organic revenue growth:
Revenue growth from continuing operations			3%
Less: effect of foreign exchange rates			2%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			2%


*(1) amounts may not sum due to rounding*

Revvity, Inc. and Subsidiaries RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES ⁽¹⁾

			Continuing Operations
			Nine Months Ended
			September 28, 2025
Organic revenue growth:
Revenue growth from continuing operations			3%
Less: effect of foreign exchange rates			0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			2%


			Life Sciences
			Nine Months Ended
			September 28, 2025
Organic revenue growth:
Revenue growth from continuing operations			2%
Less: effect of foreign exchange rates			1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			2%


			Diagnostics
			Nine Months Ended
			September 28, 2025
Organic revenue growth:
Revenue growth from continuing operations			3%
Less: effect of foreign exchange rates			0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			3%


*(1) amounts may not sum due to rounding*

Revvity, Inc. and Subsidiaries FY 2025 ORGANIC REVENUE GROWTH FORECAST ⁽¹⁾

			Continuing Operations
			Twelve Months Ended
			December 28, 2025
			*Projected*
Organic revenue growth:
Revenue growth from continuing operations			3% - 5%
Less: effect of foreign exchange rates			1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses			0%
Organic revenue growth from continuing operations			2% - 4%


*(1) amounts may not sum due to rounding*

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" or "organic growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions and asset impairments. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of revenue.

We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of revenue.

We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of revenue.

We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of investments and debt extinguishment costs.

We use the term "adjusted operating income" to refer to GAAP operating income, excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," and "adjusted operating margin" to refer to adjusted operating income as a percentage of revenue.

We use the term "free cash flow" to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations ("capital expenditures") plus the proceeds from sales of plant, property and equipment from continuing operations ("capital disposals").

We use the term "adjusted net income" to refer to GAAP income from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term "adjusted earnings per share from continuing operations," "adjusted earnings per share," "adjusted EPS," or "adjusted EPS from continuing operations" to refer to GAAP earnings per share from continuing operations, excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the value of investments, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.

Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets, deferred revenue and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.

Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.

Transformation costs—transformation costs consist of external professional service costs related to transformation initiatives focused on business processes modernization, automation, and implementation of global systems to support the new Revvity Business Model. These costs are determined to be non-capitalizable in accordance with accounting standards. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.

Asset impairments—we incur expenses related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.

Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.

Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.

Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.

Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.

Change in fair value of investments—we exclude the impact of changes in the value of investments. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, transformation costs, significant litigation matters and settlements, significant environmental charges, changes in the fair value of investments, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, and restructuring and other charges is calculated based on operational results and a blended jurisdictional tax rate, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on a blended jurisdictional tax rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251027364903/en/

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Revvity Announces Financial Results for the Third Quarter of 2025